Accelerated fourth quarter sales growth to 7.6% , organic growth* of 14.3% Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industry Provides full-year 2024 financial guidance reflecting enhanced revenue growth and improved execution DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or... Read More